The data monitoring committee overseeing the trial (known as E4A03) recommended that the survival results from a recent interim analysis be made public because of early differences being seen in overall survival rates. Researchers found that patients in the study who received low-dose dexamethasone and lenalidomide had a one-year survival of 96 percent compared to 86 percent for patients treated with the standard-dose of dexamethasone and lenalidomide. In addition, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide. Detailed results from this trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago, Ill., from June 1 to 5, 2007.
Anyone taking oral steroids or a high dose of inhaled steroids for more than three weeks should be given a steroid treatment card . Small enough to keep in your purse or wallet, this card has room to record the details of your dose and your condition(s). This is so that if you ever need any medical treatment and you're not able to communicate (you're having an asthma attack, for example), the people treating you know you're taking prednisolone and can plan your treatment accordingly. If you are taking oral steroids, or high-dose inhaled steroids, for more than three weeks then you should never suddenly stop them.